menu

Duchenne Muscular Dystrophy: Differentiating Advances in Treatment

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Duchenne Muscular Dystrophy: Differentiating Advances in Treatment 

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Omer Abdul Hamid
    Neuromuscular Neurologist
    Nemours Children’s Hospital
    Orlando, FL

    Dr. Hamid has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Site Principal: Biogen, Genentech/Roche, Scholar Rock Clinical Trials
    Advisory Board: PTC Therapeutics, Sarepta, Catalyst
    Speaker Fee: Biogen, Genentech/Roche

    Faculty:
    Migvis Monduy, MD
    Director, Neuromuscular Program
    Nicklaus Children’s Hospital
    Miami, FL

    Dr. Monduy has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fee: Catalyst Pharmaceuticals, PTC TherapeuticsSarepta

    Nancy L. Kuntz, MD
    Professor of Pediatrics and Neurology
    Northwestern Feinberg School of Medicine
    Chicago, IL

    Dr. Kuntz has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Argenx, Biogen, Catalyst, Genentech, Novartis, Sarepta
    Consulting Fee: Argenx, Catalyst, Genentech, Sarepta

    Reviewers/Content Planners/Authors:

    • Jennifer Brutsche has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Barry Fiedel, PhD. has nothing to disclose.
    • Samantha Keehn has nothing to disclose.
    • John Maeglin has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Susan Smith, MN, PhD has ownership interest in Hepion Pharmaceuticals.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Interpret data from clinical trials of a novel steroidal anti-inflammatory agent for the treatment of Duchenne muscular dystrophy (DMD). 
    2. Differentiate the comparative safety of a novel steroidal anti-inflammatory agent from classic glucocorticoids used to treat DMD.        
    3. Determine the appropriate use of a novel steroidal anti-inflammatory agent in a patient with DMD.
  • Target Audience

    This activity is designed to meet the educational needs of Neurologists, especially those with expertise in neuromuscular diseases, pediatricians, physical medicine and rehabilitation specialists, physical therapists, occupational therapists, and other members of the DMD care team.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until April 15, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Catalyst Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Omer Abdul Hamid
    Neuromuscular Neurologist
    Nemours Children’s Hospital
    Orlando, FL

    Dr. Hamid has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Site Principal: Biogen, Genentech/Roche, Scholar Rock Clinical Trials
    Advisory Board: PTC Therapeutics, Sarepta, Catalyst
    Speaker Fee: Biogen, Genentech/Roche

    Faculty:
    Migvis Monduy, MD
    Director, Neuromuscular Program
    Nicklaus Children’s Hospital
    Miami, FL

    Dr. Monduy has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fee: Catalyst Pharmaceuticals, PTC TherapeuticsSarepta

    Nancy L. Kuntz, MD
    Professor of Pediatrics and Neurology
    Northwestern Feinberg School of Medicine
    Chicago, IL

    Dr. Kuntz has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Argenx, Biogen, Catalyst, Genentech, Novartis, Sarepta
    Consulting Fee: Argenx, Catalyst, Genentech, Sarepta

    Reviewers/Content Planners/Authors:

    • Jennifer Brutsche has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Barry Fiedel, PhD. has nothing to disclose.
    • Samantha Keehn has nothing to disclose.
    • John Maeglin has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Susan Smith, MN, PhD has ownership interest in Hepion Pharmaceuticals.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Interpret data from clinical trials of a novel steroidal anti-inflammatory agent for the treatment of Duchenne muscular dystrophy (DMD). 
    2. Differentiate the comparative safety of a novel steroidal anti-inflammatory agent from classic glucocorticoids used to treat DMD.        
    3. Determine the appropriate use of a novel steroidal anti-inflammatory agent in a patient with DMD.
  • Target Audience

    This activity is designed to meet the educational needs of Neurologists, especially those with expertise in neuromuscular diseases, pediatricians, physical medicine and rehabilitation specialists, physical therapists, occupational therapists, and other members of the DMD care team.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until April 15, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Catalyst Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule29 May 2024